|
Reply To:
|
|
The state-run Haffkine Bio-Pharmaceutical Corporation Limited has developed a 'mixed anti-gas gangrene' drug which will be used to treat patients susceptible to gangrene. After six years of research, a team of scientists from Haffkine submitted its research report to the department of biotechnology.
|
|